Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Stuttgart EUR

Onco-Innovations Ltd (W1H.SG)

Compare

1.5600

-0.1800

(-10.34%)

At close: February 28 at 9:46:23 PM GMT+1

Onco-Innovations' Inka Health Innovative AI-Driven Oncology Study Paves the Way for New Research

VANCOUVER, BC / ACCESS Newswire / February 27, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its wholly-owned subsidiary, Inka Health ("Inka"), ...

ACCESS Newswire 2 days ago

ONCO.CN

W1H.F
Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile

VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its second-generation nanoparticle formulation of ...

ACCESS Newswire 5 days ago

ONCO.CN

W1H.F
Onco-Innovations Provides Information Regarding Inka Health's USPTO Provisional Patent Application for AI-Powered Precision Medicine Platform, SynoGraph

VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health ("Inka"), filed a provisional ...

ACCESS Newswire 8 days ago

ONCO.CN

W1H.F
Onco-Innovations Announces U.S. Listing on the OTCQB Market

VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its common shares have commenced trading on the OTCQB marketplace ...

ACCESS Newswire 8 days ago

W1H.F

ONCO.CN
Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study

Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H ,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusive-licensed technology, a new class of Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors (the "Technology"), ...

ACCESS Newswire 19 days ago

ONNVF
Onco-Innovations Announces Expression of Interest Between Inka Health and Global Data Leader, Quantify Research

VANCOUVER, BC / ACCESS Newswire / February 6, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. ("Inka Health") has entered into ...

ACCESS Newswire 23 days ago

W1H.F

ONCO.CN
Onco-Innovations Completes Acquisition of Inka Health to Accelerate AI-Driven Cancer Research and Drug Development

Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news release dated January 22, 2025, that it has completed the acquisition (the "Acquisition") of all of the outstanding ...

ACCESS Newswire 26 days ago

ONNVF
Onco-Innovations' Licensed Technology Shows Promise in Enhancing Chemotherapy Effectiveness by Overcoming Cancer Cell Resistance and Inhibiting Cancer Cell Repair

VANCOUVER, BC / ACCESS Newswire / January 30, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its licensed technology of a new class of PNKP (Polynucleotide Kinase ...

ACCESS Newswire 30 days ago

ONNVF
Onco-Innovations' Private Placement Fully Subscribed

VANCOUVER, BC / ACCESS Newswire / January 29, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its non-brokered private placement (the "Private Placement") of up to 408,164 ...

ACCESS Newswire last month

ONNVF
Onco-Innovations Unaware of Any Material Change

At the request of the Canadian Investment Regulatory Organization, Onco-Innovations Limited (the "Company") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent ...

ACCESS Newswire last month

ONNVF
Onco-Innovations Enters into LOI with Inka Health to Implement AI Technology Toward Cancer Detection and Drug Development

Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)("Onco" or the "Company") is pleased to announce that it has entered into a letter of intent (the "LOI") with Inka Health Corp. ("Inka Health"), an arms-length party holding a state-of-the-art ...

ACCESS Newswire last month

W1H.F

ONCO.CN
Onco-Innovations' Licensed Technology Shown in Study to Successfully Prevent Regeneration of Cancer Cells

VANCOUVER, BC / ACCESS Newswire / January 16, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusively-licensed technology, a new class of Polynucleotide Kinase ...

ACCESS Newswire last month

W1H.F

ONCO.CN
Onco-Innovations' Technology Shown in Study to Successfully Inactivate DNA Repair in Cancer, Potentially Boosting Radiation Therapy Effectiveness

VANCOUVER, BC / ACCESSWIRE / January 9, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusively-licensed technology of a new class of PNKP (Polynucleotide ...

ACCESS Newswire last month

ONCO.CN

W1H.F
Onco-Innovations Provides Information Regarding Exclusive License for Patented Drug with Potential to Enhance Cancer Treatment Options

VANCOUVER, BC / ACCESSWIRE / January 8, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusively-licensed PNKP (Polynucleotide Kinase 3'-Phosphatase) inhibitors ...

ACCESS Newswire last month

W1H.F

ONCO.CN
Canadian Securities Exchange Reports November 2024 Performance Figures

Toronto, Ontario--(Newsfile Corp. - December 19, 2024) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for November 2024.November 2024 Operating StatisticsTrading volume of CSE listed securities totaled 1.5 billion shares;Trading value of CSE listed securities was $491 million;CSE issuers completed 100 financings that raised an aggregate $292 million; andThe CSE welcomed listings from four new companies, bringing total listed securities to 777 as at

Newsfile 2 months ago

DMC.CN

BRAZ.CN

ADP.CN

Performance Overview

Return	W1H.SG	S&P/TSX Composite index
YTD	+39.78%	+3.14%
1-Year	+39.78%	+19.11%
3-Year	+39.78%	+20.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Onco-Innovations Ltd (W1H.SG)

Onco-Innovations' Inka Health Innovative AI-Driven Oncology Study Paves the Way for New Research

Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile

Onco-Innovations Provides Information Regarding Inka Health's USPTO Provisional Patent Application for AI-Powered Precision Medicine Platform, SynoGraph

Onco-Innovations Announces U.S. Listing on the OTCQB Market

Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study

Onco-Innovations Announces Expression of Interest Between Inka Health and Global Data Leader, Quantify Research

Onco-Innovations Completes Acquisition of Inka Health to Accelerate AI-Driven Cancer Research and Drug Development

Onco-Innovations' Licensed Technology Shows Promise in Enhancing Chemotherapy Effectiveness by Overcoming Cancer Cell Resistance and Inhibiting Cancer Cell Repair

Onco-Innovations' Private Placement Fully Subscribed

Onco-Innovations Unaware of Any Material Change

Onco-Innovations Enters into LOI with Inka Health to Implement AI Technology Toward Cancer Detection and Drug Development

Onco-Innovations' Licensed Technology Shown in Study to Successfully Prevent Regeneration of Cancer Cells

Onco-Innovations' Technology Shown in Study to Successfully Inactivate DNA Repair in Cancer, Potentially Boosting Radiation Therapy Effectiveness

Onco-Innovations Provides Information Regarding Exclusive License for Patented Drug with Potential to Enhance Cancer Treatment Options

Canadian Securities Exchange Reports November 2024 Performance Figures

Performance Overview